Integrin Alpha 7 (ITGA7) - Pipeline Review, H1 2018

Integrin Alpha 7 (ITGA7) - Pipeline Review, H1 2018


  • Products Id :- GMDHC1520TDB
  • |
  • Pages: 26
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Integrin Alpha 7 (ITGA7)-Pipeline Review, H1 2018

Summary

Integrin Alpha 7 (ITGA7) pipeline Target constitutes close to 9 molecules. The latest report Integrin Alpha 7 (ITGA7)-Pipeline Review, H1 2018, outlays comprehensive information on the Integrin Alpha 7 (ITGA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Integrin Alpha 7 (ITGA7)-Alpha-7 integrin is a protein encoded by the ITGA7 gene. It induces changes in the shape and mobility of myoblasts, and facilitates their localization at laminin-rich sites of secondary fiber formation. It is involved in the maintenance of the myofibers cytoarchitecture as well as for their anchorage, viability and functional integrity.

The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 4 and 4 respectively. Report covers products from therapy areas Musculoskeletal Disorders and Genetic Disorders which include indications Muscular Dystrophy and Duchenne Muscular Dystrophy.

Furthermore, this report also reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 7 (ITGA7)

- The report reviews Integrin Alpha 7 (ITGA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics and enlists all their major and minor projects

- The report assesses Integrin Alpha 7 (ITGA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Integrin Alpha 7 (ITGA7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Integrin Alpha 7 (ITGA7)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Integrin Alpha 7 (ITGA7) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Integrin Alpha 7 (ITGA7)-Overview

Integrin Alpha 7 (ITGA7)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Integrin Alpha 7 (ITGA7)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Molecule Type

Integrin Alpha 7 (ITGA7)-Companies Involved in Therapeutics Development

Strykagen Corp

Integrin Alpha 7 (ITGA7)-Drug Profiles

Stryka-232-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-234-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-425-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-516-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-516s-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-533-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-969-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-978-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

StrykaPro-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Strykagen Corp, H1 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Strykagen Corp

Integrin Alpha 7 (ITGA7) Therapeutic Products under Development, Key Players in Integrin Alpha 7 (ITGA7) Therapeutics, Integrin Alpha 7 (ITGA7) Pipeline Overview, Integrin Alpha 7 (ITGA7) Pipeline, Integrin Alpha 7 (ITGA7) Pipeline Assessment

select a license
Single User License
USD 3500 INR 248430
Site License
USD 7000 INR 496860
Corporate User License
USD 10500 INR 745290

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com